Skip to main content
Premium Trial:

Request an Annual Quote

Mitchell Fogelman, Carlo Croce

Premium
CytRx, the parent firm of RNAi drugs developer RXi Pharmaceuticals,has named Mitchell Fogelman as its new CFO.
 
Fogelman replaces Matthew Natalizio who CytRx said left to “pursue other opportunities.”
 
Fogelman has held positions with International Aluminum, an industrial products maker, and accounting firm PricewaterhouseCoopers.
 

He holds an MBA and BA from the University of California, Los Angeles.

 

 
Cepheid, a molecular diagnostics firm, has appointed Ohio State University professor and microRNA researcher Carlo Croce to its scientific advisory board.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.